Rouse and Codex announce breakthrough China Life Sciences collaboration
Market access and regulatory approval services streamlined with IP grant and protection
Rouse and Life Sciences professional services provider, Codex, announced a collaboration today that promises to give unparalleled support to life sciences companies accessing the China market.
The rapid spread of COVID-19 has intensified the global search for treatments, applications and devices. In its response to the pandemic, China’s National Medical Products Administration (NMPA) has moved to fast-track the review of drugs and medical devices that might be used to prevent or treat COVID-19. As a result, regulatory, approval and IP protection procedures are likely to undergo significant change. In this context, the opportunity of faster market access brings a heightened risk of IP exposure, meaning the collaboration of two market leaders in the fields of IP and regulatory advice could not come at a more important time for the life sciences industry.
With more than 300 China life sciences and IP experts working together, including regulatory analysts, pharmacists, consultants, translators, patent attorneys and lawyers, Rouse and Codex can now offer their life sciences clients unparalleled support, helping them navigate the NMPA’s evolving approval practices to gain prompt market access, while ensuring valuable exclusivity of IP and marketing rights.
Luke Minford, Rouse CEO, commented:
“This is a game-changing moment for life sciences globally. Never before has entering and excelling in the China market been so important to pharmaceutical, biotechnology, medical device and life sciences companies. The opportunity is huge, but businesses need to understand the nuances of patent protection and approval in China, amidst a complex and frequently changing regulatory regime. Together, Rouse and Codex are unrivalled in their ability to guide clients on this journey.”
Jean-Marie Blanc, Codex CEO, commented:
“China’s life sciences regulatory regime is undergoing rapid transformation. The new fast-track measures introduced by the National Medical Products Administration presents a major opportunity for international rights holders to gain market access, providing they can access the right advice. Our partnership with Rouse means no other firm is better placed to offer end-to-end IP advisory services built upon forensic understanding of China’s evolving regulatory rules.”